Smart Bomb Virus Shows Promise as Brain Tumor Immunotherapy
In clinical trial, 20 percent of patients with recurrent glioblastoma live 3-plus years
A common cold virus engineered to attack the most common and deadly of brain tumors allowed 20 percent of patients with recurrent glioblastoma to live for three years or longer, researchers from The University of Texas MD Anderson Cancer Center report on a phase I clinical trial.
The altered adenovirus, called Delta-24-RGD or DNX-2401, was injected one time directly into the tumors of 25 patients whose glioblastoma had recurred after surgery and other treatments, a patient group that typically has a median survival of six months.
“Of those five long-term survivors, three had durable complete responses, which is impressive for a phase I clinical trial in glioblastoma,” said lead author Frederick Lang, M.D., professor of Neurosurgery. “Many phase I trials might have one patient who does well, so our result is unusual, but we’re always cautious in assessing results with this very difficult disease.”
Click here to read more.
8th Annual EANS Young Neurosurgeons Meeting and EANS Research Course
March 22, 2018 - March 24, 2018; Oxford, United Kingdom
The Society of University Neurosurgeons Annual Meeting
March 22, 2018 - March 25, 2018; Dallas
ASN 2018 Annual Meeting
March 24-28, 2018; Riverside, CA
3rd Annual Principles and Techniques of Complex Spinal Reconstruction: A Hands-on Cadaveric Workshop
March 30, 2018 - March 31, 2018; New York
11th Annual Cervical Spine Research Society Hands-on Cadaver Course
April 12-14, 2018; St. Louis, MO
Be the first to reply using the above form.